SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Zvi Steinberg who wrote (401)1/6/1999 9:17:00 AM
From: Ariella  Respond to of 1386
 
Zvi - similar thing going on in Britain. See Yahoo thread for link. (eom)



To: Zvi Steinberg who wrote (401)1/6/1999 4:39:00 PM
From: Ariella  Read Replies (1) | Respond to of 1386
 
I just spoke with PARS and am told that, at last, ALL extra toxicity tests on LE-T are finished, as are talks with the FDA on how to set up Phase III trial protocol. My guess from what I heard is that the Phase III trial (which only takes a week) will be finished by the time we receive next eps report.

Investor relations will also receive a much bigger budget this year.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News